Cellular tumor markers in thyroid cancer;Komórkowe markery nowotworowe w raku tarczycy

Polski Merkuriusz Lekarski

Volumn 22, Issue 130, 2007, Pages 295-299

  Kopczyńska, Ewa ^a   Kwapisz, Justyna ^a   Junik, Roman ^a   Tyrakowski, Tomasz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Cellular tumor markers; Thyroid cancer

Indexed keywords

TUMOR MARKER;

ARTICLE; HUMAN; THYROID TUMOR;

HUMANS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249680660     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bojunga J., Zeuzem S.: Molecular detection of thyroid cancer: an update. Clin. Endocrinol., 2004, 61, 523-530.
2. Chen Z., Mustafa T., Trojanowicz B. i wsp.: CD82, and CD63 in thyroid cancer. Int. J. Mol. Med., 2004, 14, 517-527.
3. Chinnappa P., Taguba L, Arciaga R. i wsp.: Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J. Clin. Endocrinol. Metab., 2004, 89, 8, 3705-3709.
4. Choi Y. I., Kim M. K., Suh J. W. i wsp.: Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, E-kadherin in thyroid carcinomas. J. Korean Med. Sci., 2005, 20, 10, 853-859.
5. Chung J.: Molecular nuclear medicine using sodium/iodide symporter. Int. Congr. Ser., 2004, 1264, 3, 77-83.
6. Collins B. J., Chiapetta G., Schneider A. B. i wsp., RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J. Clin. Endocrinol. Metab., 2002, 87, 8, 3941-3946.
7. Davies H., Bignell G.R., Cox C. i wsp.: Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 6892, 946-954.
8. DeMicco C., Vassko V., Henry J.: The value of thyroid peroxidase immunohistochemistry for preoperative fine-needle aspiration diagnosis of the follicular variant of papillary thyroid cancer. Surgery, 1999, 126, 6, 1200-1204.
9. Donghi R., Longoni A., Pilotti S. i wsp.: Gene p53 mutations are restricted to poorly differentiated carcinomas of the thyroid gland. J. Clin. Invest, 1993, 91, 4, 1753-1760.
10. Fabbro D., Di Loreto C., Beltrami C.A. i wsp.: Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res., 1994, 54, 1, 4744-4749.
11. Faggiano A., Talbot M., Lacroix L. i wsp.: Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin. Endocrinol., 2002, 57, 6, 813-819.
12. Fagin J. A., Matsuo K., Karmakar A. i wsp.: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 1993, 91, 6, 179-184.
13. Garcia-Rostan G., Tallini G., Herrero A. i wsp.: Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res., 1999, 59, 4, 1811-1815.
14. Gryczyńska M.: Obraz kliniczny i diagnostyka raka rdzeniastego tarczycy oraz zespołów MEN 2A i MEN 2B. Współcz. Onkol., 2005, 9, 4, 157-160.
15. Heaney A.P., Singson R., McCabe C.J. i wsp.: Expression of pituitarytumour transforming gene in colorectal tumours. Lancet, 2000, 355, 9205, 717-719.
16. Ho T., Li G., Zhao C. i wsp.: RET polymorphisms and haplotypes and risk of differentiated thyroid cancer. Laryngoscope, 2005, 115, 6, 1035-1041.
17. Ito Y., Yoshida H., Tomoda C. i wsp.: S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology, 2004, 67, 5-6, 397-402.
18. Jarzaj D B.: Nowotwory gruczołów dokrewnych. W: Onkologia kliniczna. Krzakowski M. (red.). Wyd. Med. Borgis, Warszawa 2001, 716-753.
19. Karga H., Lee J., Vickery A. L. i wsp.: Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab., 1991, 73, 4, 832-836.
20. Kebebew E., Peng M., Treseler P.A. i wsp.: Id1 gene expression is upregulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J. Clin. Endocrinol. Metab., 2004, 89, 12, 6105-6111.
21. Kim D.S., McCabe C.J., Buchanan M.A. i wsp.: Oncogenes in thyroid cancer. Clin. Otolaryngol., 2003, 28, 386-395.
22. Kroll T.G., Sarraf P., Pecciarini L. i wsp.: PAX-PPAR? fusion in oncogene human thyroid carcinoma. Science, 2000, 289, 1357-1360.
23. Le H.N., Norton J.A.: Perspective on RET proto-oncogene and thyroid cancer. Cancer J., 2000, 6, 2, 50-57.
24. Learoyd D.L., Messina M., Zedenius J. i wsp.: RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J. Clin. Endocrinol. Metab., 1998, 83, 10, 3631-3635.
25. Makarewicz J., Lewiński A.: Czynniki rokownicze w zróżnicowanym raku tarczycy. Post. Hig. Med. Dośw., 2004, 58, 514-521.
26. Matsuo S.E., Martins L., Leoni S.G. i wsp.: Biological markers in thyroid tumors. Arg. Bras. Endocrinol. Metab., 2004, 48, 1, 114-125.
27. McCabe C.J., Boelaert K., Tannahill L.A. i wsp.: Vascular endothelial growth factor, its receptor KDR/Flk-1, pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab., 2002, 87, 9, 4238-1244.
28. Motti M.L., Califano D., Baldassarre G. i wsp.: Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis, 2005, 26, 6, 1021-1034.
29. Narimatsu M., Nagayama Y., Akino K. i wsp.: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J. Clin. Endocrinol. Metab., 1998, 83, 10, 3668-3672.
30. Niedziela M., Brȩborowicz D., Kulińska-Niedziela I. i wsp.: Rak rdzeniasty u dzieci. Współcz. Onkol., 2005, 9, 4, 161-165.
31. Nikiforova M.N., Lynch R.A., Biddinger P.W. i wsp.: RAS point mutations and PAX-PPARy rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab., 2003, 88, 5, 2318-2326.
32. Norton J.N.: Nowotwory gruczołów dokrewnych. W: Podrȩcznik onkologii klinicznej. Pawlȩga J. (red.). Wyd. Przeglad Lek., Kraków 2001, 345-370.
33. Paunović I.: Differentiated thyroid cancer: growth factors, oncogenes and environmental influences. Arch. Oncol., 2003, 11, 3, 171-172.
34. Peyssonnaux C., Eychene A.: The Raf/MEK/ERK pathway - new concepts of activation. Biol. Cell, 2001, 93, 1-2, 53-62.
35. Prasad M., Pellegata N.S., Huang Y. i wsp.: Galectin-3, fibronectin-1, Cl-TED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod. Pathol., 2005, 18, 1, 48-57.
36. Rekomendacje Polskich Towarzystw Naukowych przyjȩte przez Komitet Naukowy II Konferencji "Rak Tarczycy", Szczyrk 2000.
37. Romei C., Elisei R., Pinchera A. i wsp.: Somatic mutations of the retprotooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J. Clin. Endocrinol. Metab., 1996, 81, 4, 19-22.
38. Sahoo S., Hoda S.A., DeLellis R.A.: Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am. J. Clin. Pathol., 2001, 116, 5, 696-702.
39. Stachlewska-Nasfeter E.: Rak tarczycy. W: Onkologia - podrȩcznik dla studentów medycyny. Kułakowski A., Skowrońska-Gardas A. (red.). PZWL, Warszawa 2003, 135-140.
40. Takai N., Hamanaka R., Yoshimatsu J. i wsp.: Polo-like kinases (Plks) and cancer. Oncogene, 2005, 24, 2, 287-291.
41. Ward L.S., Santarosa P.L., Granja F. i wsp.: Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett., 2003, 200, 10, 85-91.
42. Xing M.: BRAF mutation in thyroid cancer. Endocr. Relat. Cancer, 2005, 12, 2, 245-262.
43. Xu X., Quiros M., Gattuso P. i wsp.: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res., 2003, 63, 15, 4561-4567.
44. Zedenius J., Larsson C., Bergholm U. i wsp.: Mutations of codon 918 in the RET protooncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J. Clin. Endocrinol. Metab., 1995, 80, 10, 1088-3090.
45. Ziemnicka K., Kaczmarek M., Hoppe-Gołȩbiewska J. i wsp.: Diagnostyka molekularna dziedzicznej postaci raka rdzeniastego tarczycy. Wspolcz. Onkol., 2005, 9, 4, 175-177.
46. Zou M., Famulski K.S., Pafhar R.S. i wsp.: Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J. Clin. Endocrinol. Metab., 2004, 89, 12, 6146-6154.